Defining new reference intervals for serum free light chains in individuals with chronic kidney disease : Results of the iStopMM study

• Published in: Blood Cancer Journal
• Main Authors: Long, Þórir Einarsson, Indriðason, Ólafur Skúli, Pálsson, Runólfur, Rögnvaldsson, Sæmundur, Löve, Þorvarður Jón, Thorsteinsdóttir, Sigrún, Sverrisdóttir, Ingigerður S, Viðarsson, Brynjar, Önundarson, Páll Torfi, Agnarsson, Bjarni Agnar, Sigurðardóttir, Margrét, Þorsteinsdóttir, Ingunn, Ólafsson, Ísleifur, Thordardottir, Asdis Rosa, Eyþórsson, Elías Sæbjörn, Jónsson, Ásbjörn, Gíslason, Gauti Kjartan, Ólafsson, Andri, Steingrímsdóttir, Hlíf, Hultcrantz, Malin, Durie, Brian G.M., Harding, Stephen, Landgren, Ola, Kristinsson, Sigurður Yngvi
• Other Authors: Internal Medicine and Emergency Services, Other departments, Faculty of Medicine, Clinical Laboratory Services, Diagnostics and Blood Bank, Office of Division of Clinical Services II, Cancer Center, University of Iceland, Landspitali - The National University Hospital of Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2022
• Subjects: Lífefna- og sameindalíffræði; Blóðlæknisfræði; Myndgreining (læknisfræði); Nýrnalæknisfræði; Meinafræði; Gigtarlæknisfræði; Humans; Immunoglobulin Light Chains; Immunoglobulin lambda-Chains; Prospective Studies; Reference Values; Renal Insufficiency; Chronic/diagnosis; Hematology; Oncology; Lambda; Rodger; Iceland
• Online Access: https://hdl.handle.net/20.500.11815/3484; https://doi.org/10.1038/s41408-022-00732-3

Funding Information: Dr. Landgren has received grant support from: NCI/NIH, FDA, LLS, Rising Tide Foundation, Memorial Sloan Kettering Cancer Center, MMRF, IMF, Paula, and Rodger Riney Foundation, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; has received honoraria for scientific talks/participated in advisory boards for: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by: Takeda, Merck, Janssen, Theradex. Dr. Hultcrantz has recevied grant support from GSK, Amgen, Daiichi Sankyo, Cosette Pharmaceuticals, and has received honoraria for scientific talks/participated in advisory boards for BMS, Curio Science, and Intellisphere LLC. All other authors declare no potential conflicts of interest. Funding Information: Dr. Kristinsson has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. Dr. Long has received research funding from the Icelandic Center for Research (Rannís). Dr. Landgren thanks Sylvester Comprehensive Cancer Center Core Grant (P30 CA240139) and Paula and Rodger Riney Foundation for support of his research. Dr. Hultcrantz thanks the Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748). The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research. Screening tests for the iStopMM study are performed by The Binding Site Ltd. Birmingham, UK. Additional funding is provided by the University of Iceland, Landspitali–The National University Hospital, and the Icelandic Cancer Society. Funding Information: Dr. Kristinsson has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. Dr. Long has received research ...